Roche NimbleGen and Baylor College Develop an Improved Version of Sequence Capture 385K Arrays
News Nov 05, 2008
Roche NimbleGen in cooperation with the Human Genome Sequencing Center at Baylor College of Medicine in Houston, Texas has launched an improved version of their Sequence Capture 385K Arrays, the groundbreaking technology for enriching targeted genomic regions for high-throughput sequencing.
The new and improved microarrays allow researchers to perform their own capture experiment and perform quick sequencing of enriched regions using next-generation technology such as the Genome Sequencer FLX System from 454 Life Sciences.
The entire workflow, starting from genomic DNA, to enriched DNA of target regions, and sequencing results takes about two weeks, compared to months or years for traditional PCR-based methods coupled with capillary sequencing. These second version microarrays will also be available through Roche NimbleGen´s Sequence Capture Service.
A critical performance measurement for enrichment technologies is to capture all the target regions with equal efficiency. NimbleGen second generation Sequence Capture Arrays deliver improved performance regarding the specificity and uniformity of captured regions.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.